항우울제로 새롭게 등장한 ‘남용 물질’ - 치료에 적용할 때 고려해야 할 것들은 무엇인가?
“Drugs of Abuse” as “New Antidepressants”: - Medical and Philosophical Considerations in Treatment
0
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Recently, drugs with a potential for abuse are regaining attention as antidepressants. These drugs are mood enhancers and reduce negative feelings. Therefore, they can be effective in the treatment of depression. However, mood enhancement is insufficient for the real improvement of depressive symptoms. Additionally, treating depression using drugs with dependency risks raises concerns regarding autonomy issues. In this article, the authors discuss issues that a psychiatrist should consider when prescribing “drugs of abuse” as antidepressants from medical, philosophical, and legal perspectives. The limitations of the current psychiatric diagnosis system in depression, questions concerning pleasure-seeking with antidepressants, dilemmas with autonomy, and problems of enhancement are discussed.
Abstract
Recently, drugs with a potential for abuse are regaining attention as antidepressants. These drugs are mood enhancers and reduce negative feelings. Therefore, they can be effective in the treatment of depression. However, mood enhancement is insufficient for the real improvement of depressive symptoms. Additionally, treating depression using drugs with dependency risks raises concerns regarding autonomy issues. In this article, the authors discuss issues that a psychiatrist should consider when prescribing “drugs of abuse” as antidepressants from medical, philosophical, and legal perspectives. The limitations of the current psychiatric diagnosis system in depression, questions concerning pleasure-seeking with antidepressants, dilemmas with autonomy, and problems of enhancement are discussed.
참고문헌 (30)
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders" (2013), American Psychiatric Association
- World Health Organization, "The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines" (1992), World Health Organization
- 강웅구, "정신과 진단체계에 대한 역사적 고찰 : 우울증 개념을 중심으로", 신경정신의학, 53(5), pp.259~292 (2014), 대한신경정신의학회[DOI]
- Kang UG, "Psychopathology: a conceptual approach to psychopathology", pp.298~356 (2021), Seoul National University Publication Center
- Hamilton M, "Development of a rating scale for primary depressive illness", Br J Soc Clin Psychol, 6, pp.278~296 (1967)
- 박혜원, "한국판 해밀턴 우울증평가척도(K-HDRS)의 확인적 요인 분석", 신경정신의학, 48(1), pp.21~28 (2009), 대한신경정신의학회
- 이중서, "한국판 Hamilton 우울증 평가 척도의 신뢰도, 타당도 연구", 신경정신의학, 44(4), pp.456~465 (2005), 대한신경정신의학회
- Khan A, "Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials", Int Clin Psychopharmacol, 17, pp.281~285 (2002)
- Montgomery SA, "A new depression scale designed to be sensitive to change", Br J Psychiatry, 134, pp.382~389 (1979)
- Cuthbert B, "The data of diagnosis : new approaches to psychiatric classification", Psychiatry, 73, pp.311~314 (2010)
- Browne CA, "Targeting opioid dysregulation in depression for the development of novel therapeutics", Pharmacol Ther, 201, pp.51~76 (2019)
- Daly EJ, "Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial", JAMA Psychiatry, 75, pp.139~148 (2018)
- Daly EJ, "Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial", JAMA Psychiatry, 76, pp.893~903 (2019)
- Fedgchin M, "Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1)", Int J Neuropsychopharmacol, 22, pp.616~630 (2019)
- Popova V, "Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression:a randomized double-blind active-controlled study", Am J Psychiatry, 176, pp.428~438 (2019)
- Ochs-Ross R, "Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression—TRANSFORM-3", Am J Geriatr Psychiatry, 28, pp.121~141 (2020)
- Ng J, "Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression : a systematic review", J Affect Disord, 293, pp.285~294 (2021)
- Taylor JS, "Willing addicts, unweilling additicts, and acting of one’s own free will", Philosophia, 33, pp.237~262 (2005)
- O’Keefe T, "Epicureanism" (2009), Routledge
- 박창증, "진화정신의학 II-진화적 관점에서 본 정신기능 및정신질환", 신경정신의학, 57(2), pp.173~189 (2018), 대한신경정신의학회[DOI]
- Park S, "What is addiction? Pathophysiology and therapeutic implications (I)", J Korean Acad Addict Psychiatry, 18, pp.3~16 (2014)
- "Paternalism"[URL]
- Mill JS, "On liberty" (1859), The Walter Scott Publishing Co
- Houska A, "Patients’ autonomy at the end of life : a critical review", J Pain Symptom Manage, 57, pp.835~845 (2019)
- Arrieta Valero I, "Autonomies in interaction: dimensions of patient autonomy and non-adherence to treatment", Front Psychol, 10, pp.1857~ (2019)
- van Randenborgh A, "Decision making in depression : differences in decisional conflict between healthy and depressed individuals", Clin Psychol Psychother, 17, pp.285~298 (2010)
- Frankfurt HG, "The importance of what we care about: philosophical essays", pp.11~25 (1988), Cambridge University Press
- Kramer PD, "Listening to prozac" (1997), Penguin Books
- DeGrazia D, "Prozac, enhancement, and self-creation", Hastings Cent Rep, 30, pp.34~40 (2000)
- Hasin DS, "Diagnosing prescription opioid use disorder in patients using prescribed opioids for chronic pain", Am J Psychiatry, 179, pp.715~725 (2022)